The dirty aspects of fecal microbiota transplantation: a review of its adverse effects and complications

Current Opinion in Pharmacology

Volumn 49, Issue , 2019, Pages 29-33

  Dailey, Francis E ^a   Turse, Erica P ^b   Daglilar, Ebubekir ^a   Tahan, Veysel ^a  

^a University of Missouri   (United States)

^b ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADVERSE OUTCOME; AUTOIMMUNE DISEASE; AWARENESS; CLOSTRIDIUM DIFFICILE INFECTION; COLON CANCER; CONSTIPATION; CROHN DISEASE; DIARRHEA; DISEASE SEVERITY; FECAL MICROBIOTA TRANSPLANTATION; FEVER; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; METABOLIC SYNDROME X; MORTALITY; NONHUMAN; OBESITY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; ADVERSE EVENT; ANIMAL; RISK;

ANIMALS; FECAL MICROBIOTA TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; RISK;

EID: 85065551646     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2019.04.008     Document Type: Review

References (30)

1. Cammarota, G., Ianiro, G., Tilg, H., Rajilic-Stojanovic, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66 (2017), 569–580.
2. Bunnik, E.M., Aarts, N., Chen, L.A., Physicians must discuss potential long-term risks of fecal microbiota transplantation to ensure informed consent. Am J Bioeth 17 (2017), 61–63.
3. van Beurden, Y.H., de Groot, P.F., van Nood, E., Nieuwdorp, M., Keller, J.J., Goorhuis, A., Complications, effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J 5 (2017), 868–879.
4. Wang, S., Xu, M., Wang, W., Cao, X., Piao, M., Khan, S., Yan, F., Cao, H., Wang, B., Systematic review: adverse events of fecal microbiota transplantation. PLoS One, 11, 2016, e0161174.
5. Greenberg, S.A., Youngster, I., Cohen, N.A., Livovsky, D.M., Strahilevitz, J., Israeli, E., Melzer, E., Paz, K., Fliss-Isakov, N., Maharshak, N., Five years of fecal microbiota transplantation – an update of the Israeli experience. World J Gastroenterol 24 (2018), 5403–5414.
6. Wang, J.W., Kuo, C.H., Kuo, F.C., Wang, Y.K., Hsu, W.H., Yu, F.J., Hu, H.M., Hsu, P.I., Wang, J.Y., Wu, D.C., Fecal microbiota transplantation: review and update. J Formos Med Assoc 118:Suppl. 1 (2019), 23–31.
7. Sunkara, T., Rawla, P., Ofosu, A., Gaduputi, V., Fecal microbiota transplant – a new frontier in inflammatory bowel disease. J Inflamm Res 11 (2018), 321–328.
8. Baxter, M., Colville, A., Adverse events in faecal microbiota transplant: a review of the literature. J Hosp Infect 92 (2016), 117–127.
9. Quraishi, M.N., Widlak, M., Bhala, N., Moore, D., Price, M., Sharma, N., Iqbal, T.H., Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 46 (2017), 479–493 This article provides the most recent, largest systematic review and meta-analysis specifically analyzing adverse effects from FMT administration, including mortality.
10. Vermeire, S., Joossens, M., Verbeke, K., Wang, J., Machiels, K., Sabino, J., Ferrante, M., Van Assche, G., Rutgeerts, P., Raes, J., Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis 10 (2016), 387–394.
11. Kelly, C.R., Ihunnah, C., Fischer, M., Khoruts, A., Surawicz, C., Afzali, A., Aroniadis, O., Barto, A., Borody, T., Giovanelli, A., et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 109 (2014), 1065–1071.
12. Mattila, E., Uusitalo-Seppala, R., Wuorela, M., Lehtola, L., Nurmi, H., Ristikankare, M., Moilanen, V., Salminen, K., Seppala, M., Mattila, P.S., et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 142 (2012), 490–496.
13. Rossen, N.G., MacDonald, J.K., de Vries, E.M., D'Haens, G.R., de Vos, W.M., Zoetendal, E.G., Ponsioen, C.Y., Fecal microbiota transplantation as novel therapy in gastroenterology: a systematic review. World J Gastroenterol 21 (2015), 5359–5371.
14. Vindigni, S.M., Surawicz, C.M., Fecal microbiota transplantation. Gastroenterol Clin North Am 46 (2017), 171–185.
15. Iqbal, U., Anwar, H., Karim, M.A., Safety and efficacy of encapsulated fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review. Eur J Gastroenterol Hepatol 30 (2018), 730–734.
16. Sha, S., Liang, J., Chen, M., Xu, B., Liang, C., Wei, N., Wu, K., Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment Pharmacol Ther 39 (2014), 1003–1032.
17. Holleran, G., Scaldaferri, F., Ianiro, G., Lopetuso, L., Mc Namara, D., Mele, M.C., Gasbarrini, A., Cammarota, G., Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection: an update. Drugs Today (Barc)54 (2018), 123–136.
18. Shogbesan, O., Poudel, D.R., Victor, S., Jehangir, A., Fadahunsi, O., Shogbesan, G., Donato, A., A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients. Can J Gastroenterol Hepatol, 2018, 2018 1394379 This is the largest, most recent systematic review examining FMT for immunocompromised individuals infected with CDI.
19. Webb, B.J., Brunner, A., Ford, C.D., Gazdik, M.A., Petersen, F.B., Hoda, D., Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis 18 (2016), 628–633.
20. Hefazi, M., Patnaik, M.M., Hogan, W.J., Litzow, M.R., Pardi, D.S., Khanna, S., Safety and efficacy of fecal microbiota transplant for recurrent Clostridium difficile infection in patients with cancer treated with cytotoxic chemotherapy: a single-institution retrospective case series. Mayo Clin Proc 92 (2017), 1617–1624.
21. Cheng, Y.W., Phelps, E., Ganapini, V., Khan, N., Ouyang, F., Xu, H., Khanna, S., Tariq, R., Friedman-Moraco, R.J., Woodworth, M.H., et al. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: a multicenter experience. Am J Transplant, 2018 This large recent study evaluated FMT for recurrent and severe CDI in 94 solid organ transplant recipients.
22. Qazi, T., Amaratunga, T., Barnes, E.L., Fischer, M., Kassam, Z., Allegretti, J.R., The risk of inflammatory bowel disease flares after fecal microbiota transplantation: systematic review and meta-analysis. Gut Microbes 8 (2017), 574–588 This article provides a recent, large-scale systematic review and meta-analysis detailing the rate of worsening IBD activity following FMT administration.
23. Chen, T., Zhou, Q., Zhang, D., Jiang, F., Wu, J., Zhou, J.Y., Zheng, X., Chen, Y.G., Effect of faecal microbiota transplantation for treatment of Clostridium difficile infection in patients with inflammatory bowel disease: a systematic review and meta-analysis of cohort studies. J Crohns Colitis 12 (2018), 710–717.
24. Wang, H., Cui, B., Li, Q., Ding, X., Li, P., Zhang, T., Yang, X., Ji, G., Zhang, F., The safety of fecal microbiota transplantation for Crohn's disease: findings from a long-term study. Adv Ther 35 (2018), 1935–1944.
25. Shi, Y., Dong, Y., Huang, W., Zhu, D., Mao, H., Su, P., Fecal microbiota transplantation for ulcerative colitis: a systematic review and meta-analysis. PLoS One, 11, 2016, e0157259.
26. Narula, N., Kassam, Z., Yuan, Y., Colombel, J.F., Ponsioen, C., Reinisch, W., Moayyedi, P., Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis 23 (2017), 1702–1709 This was a recent, large systematic review and meta-analysis evaluating FMT for patients with active UC. This study includes all four clinical trials to date examining FMT for patients with UC.
27. Alang, N., Kelly, C.R., Weight gain after fecal microbiota transplantation. Open Forum Infect Dis, 2, 2015 ofv004.
28. Ridaura, V.K., Faith, J.J., Rey, F.E., Cheng, J., Duncan, A.E., Kau, A.L., Griffin, N.W., Lombard, V., Henrissat, B., Bain, J.R., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science, 341, 2013 1241214.
29. Schwartz, M., Gluck, M., Koon, S., Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am J Gastroenterol, 108, 2013, 1367.
30. Zhang, F., Cui, B., He, X., Nie, Y., Wu, K., Fan, D., FMT-standardization Study Group, Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell 9 (2018), 462–473.